Regeneron Pharmaceuticals (REGN) Stock Price, Fundamentals & Analysis

What REGN does

Regeneron Pharmaceuticals (REGN) discovers, develops, manufactures, and commercialises medicines to treat a wide range of diseases worldwide. Its portfolio includes treatments for eye conditions such as wet age-related macular degeneration, allergic and inflammatory diseases, cardiovascular and metabolic disorders, neurological conditions, infectious diseases, rare diseases, and cancer. Key products include EYLEA injections, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. The company also has licensing and collaboration agreements with partners such as Bayer and Alnylam Pharmaceuticals. Regeneron is part of the S&P 500 and operates in the biotechnology sector alongside peers like Illumina, Inc. (ILMN) and Pfizer (PFE).

Key numbers explained

• $801.82 is the current share price, reflecting what investors pay for one share on the US market.
• The trailing P/E ratio of 19.8 shows how much the market is willing to pay per dollar of the company's last 12 months' earnings; a lower figure can suggest a stock is relatively cheaper compared to its earnings.
• The forward P/E ratio of 13.2 uses expected future earnings, which can make the stock look more attractive if those expectations hold.
• $40.44 is the earnings per share (EPS) over the trailing 12 months, representing the portion of profit allocated to each outstanding share.
• The dividend yield of 0.47% indicates the annual dividend payment as a percentage of the share price; the ex-dividend date is 18 Aug 2026.
• 9% of earnings are paid out as dividends, meaning the company retains most of its profit for reinvestment.
• A beta of 0.19 suggests the stock is historically much less volatile than the overall market.
• The 52-week range of 541 – 859.34 shows the lowest and highest prices over the past year, with the current price near the upper end.

Recent news

Recent headlines highlight Regeneron's EYLEA HD momentum and Dupixent growth alongside pipeline catalysts. Other stories note Sanofi reviewing its pipeline and expanding its M&A hunt ahead of patent losses, while separate articles discuss broader biopharma trends and stock valuation perspectives.

What to watch

Investors typically monitor pipeline progress and product approvals, as new clinical data can shift sentiment. Licensing deals and collaborations, such as those with Bayer and Alnylam, can also influence the company's trajectory. Broader factors include sector trends in biotechnology, regulatory developments, and the competitive landscape alongside peers like CVS Health (CVS) and Edwards Lifesciences (EW).